Skip to content

Released Mar 12, 2013, after the close

10-K filed Mar 12, 2013, 71 days after period end · 0001193125-13-103307

Q4 2012 · 10-K
Revenue$1.44Mno prior Q4 2011 on file−33.7% vs Q3 2012
Net Income-$19.68MN/M vs Q4 2011N/M vs Q3 2012
EPS, diluted—
Gross Profit$1,229,000—
Operating Cash Flowderived-$5,178,000N/M
Margins · derived
Gross margin85.6%
Net margin-1370.3%

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2012Q4 2011derived from reported figuresQ4 2010derived from reported figures
Revenue$1.44M——
Net Income-$19.68M$1.59M—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR